Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol: Observational study in young postadolescent women

Contraception

Volumn 70, Issue 4, 2004, Pages 293-298

  Paoletti, Anna Maria ^a   Orrù, Marisa ^a   Lello, Stefano ^a   Floris, Stefano ^a   Ranuzzi, Francesca ^a   Etzi, Rossella ^a   Zedda, Pierina ^a   Guerriero, Stefano ^a   Fratta, Stefania ^a   Sorge, Roberto ^b   Mallarini, Giorgio ^a   Melis, Gian Benedetto ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Bone specific alkaline phosphatase; Deoxypyridinoline; Drospirenone; Free androgenization index; Osteocalcin; Pyridinoline; SHBG; Testosterone

Indexed keywords

ALKALINE PHOSPHATASE; DEOXYPYRIDINOLINE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; OSTEOCALCIN; PROGESTERONE; PYRIDINOLINE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; ORAL CONTRACEPTION; OUTCOMES RESEARCH;

ADULT; ALKALINE PHOSPHATASE; AMINO ACIDS; ANDROSTENES; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; BONE REMODELING; CONTRACEPTIVES, ORAL; CREATININE; ETHINYL ESTRADIOL; FEMALE; HUMANS; OSTEOCALCIN; PROGESTERONE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; WAIST-HIP RATIO;

EID: 4644371788     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2004.04.004     Document Type: Article

References (43)

1. Fabbri G., Petraglia F., Segre A., et al. Reduced spinal bone density in young women with amenorrhoea. Eur J Obstet Gynecol Reprod Biol. 41:1991;117-122
2. Davies M.C., Hall M.L., Jacobs H.S. Bone mineral loss in young women with amenorrhoea. Br Med J. 301:1990;790-793
3. Drinkwater B.L., Brummer B., Chesnut C.H. III. Menstrual history as a determinant of current bone density in young athletes. J Am Med Assoc. 263:1990;545-548
4. Metka M., Holzer G., Heytmanek G., Huber J. Hypergonadotropic hypogonadic amenorrhea (World Health Organization III) and osteoporosis. Fertil Steril. 57:1992;37-41
5. Paoletti A.M., Serra G.G., Cagnacci A., et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril. 65:1996;707-710
6. Garnero P., Sornay-Rendu E., Delmas P.D. Decreased bone turnover in oral contraceptive users. Bone. 16:1995;499-503
7. Paoletti A.M., Orrù M., Floris S., et al. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception. 61:2000;259-263
8. Castelo-Branco C., Martinez de Osaba M.J., Pons F., Vanrell J.A. Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel results of a 2-year follow-up. Eur J Contracept Reprod Health Care. 3:1998;79-84
9. Mais V., Fruzzetti F., Ajossa S., Paoletti A.M., Guerriero S., Melis G.B. Bone metabolism in young women taking a monophasic pill containing 20 mcg ethinylestradiol a prospective study. Contraception. 48:1993;445-452
10. Nappi C., Di Spiezio Sardo A., Acunzo G., et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women a prospective controlled randomized study. Contraception. 67:2003;355-359
11. Berenson A.B., Radecki C.M., Grady J.J., Rickert V.I., Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 98:2001;576-582
12. Naessen T., Olsson S.E., Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception. 52:1995;35-39
13. Cromer B.A., Blair J.M., Mahan J.D., Zibners L., Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 129:1996;671-676
14. Gunther D.F., Underwood L.E., Calikoglu A.S. Androgen-accelerated bone maturation in mice is not attenuated by Faslodex, an estrogen receptor blocker. Bone. 28:2001;410-413
15. Chen Q., Kaji H., Sugimoto T., Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 491:2001;91-93
16. Janaud A., Rouffy J., Upmalis D., Dain M.P. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl. 156:1992;33-38
17. Carr B.R. Uniqueness of oral contraceptive progestins. Contraception. 58:(Suppl):1998;23S-27S
18. Jordan V.C., Jeng M.H., Catherino W.H., Parker C.J. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer. 71:(Suppl):1993;1501-1505
19. Oelkers W., Berger V., Bolik A., et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. Clin Endocrinol Metab. 73:1991;837-842
20. Pollow K., Juchem M., Elger W., Jacobi N., Hoffmann G., Mobus V. Dihydrospirorenone (ZK30595) a novel synthetic progestagen characterization of binding to different receptor proteins. Contraception. 46:1992;561-574
21. Muhn P., Krattenmacher R., Beier S., Elger W., Schillinger E. Drospirenone a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception. 51:1995;99-110
22. Apter D., Borsos A., Baumgartner W., et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 8:2003;37-51
23. Paoletti A.M., Lello S., Fratta S., et al. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg ethinyl estradiol. Fertil Steril. 81:2004;645-651
24. Gregoriou O., Bakas P., Konidaris S., Papadias K., Mathiopoulos D., Creatsas G. The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women. Gynecol Endocrinol. 14:2000;369-373
25. World Health Organization. Improving access to quality care in family planning - medical eligibility criteria for contraceptive use. 1996;World Health Organization, Geneva
26. Bonjour J.P., Theintz G., Buchs B., Slosman D., Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab. 73:1991;555-563
27. Katzman D.K., Bachrach L.K., Carter D.R., Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab. 73:1991;1332-1339
28. Nelson D.A., Simpson P.M., Johnson C.C., Barondess D.A., Kleerekoper M. The accumulation of whole body skeletal mass in third- and fourth-grade children effects of age, gender, ethnicity, and body composition. Bone. 20:1997;73-78
29. Gundberg C.M., Looker A.C., Nieman S.D., Calvo M.S. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone. 31:2002;703-708
30. Vesper H.W., Demers L.M., Eastell R., et al. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chem. 48:2002;220-235
31. Zittermann A., Schwarz I., Scheld K., et al. Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J Clin Endocrinol Metab. 85:2000;95-101
32. Kullenberg R. Reference database for dual X-ray and laser Calscan bone densitometer. J Clin Densitom. 6:2003;367-372
33. Mathur R.S., Moody L.O., Landgrebe S., Williamson H.O. Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril. 35:1981;29-35
34. Morley J.E., Patrick P., Perry H.M. 3rd. Evaluation of assays available to measure free testosterone. Metabolism. 51:2002;554-559
35. Delmas P.D. The role of markers of bone turnover in the assessment of fracture risk in postmenopausal women. Osteoporos Int. 8:(Suppl 1):1998;S32-S36
36. Delmas P.D. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone. 13:(Suppl 1):1992;S17-S21
37. Delmas P.D., Schlemmer A., Gineyts E., Riis B., Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 6:1991;639-644
38. Bjarnason N.H., Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone. 26:2000;561-569
39. Bruyere O., Collette J., Delmas P., et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas. 44:2003;259-265
40. van Vloten W.A., van Haselen C.W., van Zuuren E.J., Gerlinger C., Heithecker R. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 69:(4 Suppl):2002;2-15
41. Wiegratz I., Jung-Hoffmann C., Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 51:1995;341-346
42. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin recent advances. Endocr Rev. 11:1990;80-91
43. Endrikat J., Mih E., Dusterberg B., et al. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 μg or 30 μg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception. 69:2004;179-187